Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Several clinical scenarios for plasma transfusion are repeatedly identified in audits, including treatment of bleeding in association with laboratory evidence of coagulopathy, correction of disseminated intravascular coagulation, prevention of intraventricular hemorrhage, management of critically ill neonates (eg, during sepsis or as a volume expander), or correction of markers of prolonged coagulation in the absence of bleeding. The findings of at least one national audit of transfusion practice indicated that almost half of plasma transfusions are given to neonates with abnormal coagulation values with no evidence of active bleeding, despite the limited evidence base to support the effectiveness of this practice. Plasma transfusions to neonates should be considered in the clinical context of bleeding (eg, vitamin K dependent), disseminated intravascular coagulation, and very rare inherited deficiencies of coagulation factors. There seems to be no role for prophylactic plasma to prevent intraventricular hemorrhage or for use as a volume expander.

Original publication

DOI

10.1016/j.tmrv.2016.07.001

Type

Journal article

Journal

Transfus Med Rev

Publication Date

10/2016

Volume

30

Pages

174 - 182

Keywords

Evidence-based medicine, Infant, Newborn, Plasma, Blood Coagulation, Blood Coagulation Disorders, Blood Component Transfusion, Blood Preservation, Evidence-Based Medicine, Hematology, Hemorrhage, Humans, Infant, Newborn, Infant, Premature, Intensive Care, Neonatal, Plasma, Platelet Transfusion, Randomized Controlled Trials as Topic, Retrospective Studies